[go: up one dir, main page]

MX2023011608A - Metodos para inhibir ras. - Google Patents

Metodos para inhibir ras.

Info

Publication number
MX2023011608A
MX2023011608A MX2023011608A MX2023011608A MX2023011608A MX 2023011608 A MX2023011608 A MX 2023011608A MX 2023011608 A MX2023011608 A MX 2023011608A MX 2023011608 A MX2023011608 A MX 2023011608A MX 2023011608 A MX2023011608 A MX 2023011608A
Authority
MX
Mexico
Prior art keywords
methods
inhibit ras
ras
inhibit
ras proteins
Prior art date
Application number
MX2023011608A
Other languages
English (en)
Inventor
Robert J Nichols
Ryan B Corcoran
Original Assignee
Massachusetts Gen Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Gen Hospital filed Critical Massachusetts Gen Hospital
Publication of MX2023011608A publication Critical patent/MX2023011608A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La descripción presenta métodos para inhibir proteínas RAS, por ejemplo, proteínas RAS que han adquirido resistencia a uno o más inhibidores de RAS. La descripción también utiliza métodos para el tratamiento del cáncer.
MX2023011608A 2021-04-02 2022-04-01 Metodos para inhibir ras. MX2023011608A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163170292P 2021-04-02 2021-04-02
US202163192843P 2021-05-25 2021-05-25
PCT/US2022/023133 WO2022212894A1 (en) 2021-04-02 2022-04-01 Methods for inhibiting ras

Publications (1)

Publication Number Publication Date
MX2023011608A true MX2023011608A (es) 2023-12-14

Family

ID=83456876

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023011608A MX2023011608A (es) 2021-04-02 2022-04-01 Metodos para inhibir ras.

Country Status (12)

Country Link
US (1) US20240108630A1 (es)
EP (1) EP4320143A4 (es)
JP (1) JP2024512767A (es)
KR (1) KR20240004436A (es)
AU (1) AU2022249177A1 (es)
BR (1) BR112023020182A2 (es)
CA (1) CA3214155A1 (es)
CR (1) CR20230500A (es)
IL (1) IL307396A (es)
MX (1) MX2023011608A (es)
TW (1) TW202308632A (es)
WO (1) WO2022212894A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL320513A (en) 2019-11-04 2025-06-01 Revolution Medicines Inc RAS inhibitors
US11690915B2 (en) 2020-09-15 2023-07-04 Revolution Medicines, Inc. Ras inhibitors
CR20230558A (es) 2021-05-05 2024-01-24 Revolution Medicines Inc Inhibidores de ras para el tratamiento del cáncer
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
WO2023199180A1 (en) * 2022-04-11 2023-10-19 Novartis Ag Therapeutic uses of a krasg12c inhibitor
JP2025519199A (ja) * 2022-06-01 2025-06-24 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト がんの治療のためのハロインドール大環状化合物
CN117720555A (zh) * 2022-09-19 2024-03-19 杭州阿诺生物医药科技有限公司 一种制备kras抑制剂化合物的中间体及其合成方法
EP4582426A4 (en) * 2022-09-19 2025-12-24 Adlai Nortye Biopharma Co Ltd PAN-KRAS INHIBITOR COMPOUND
KR20250085767A (ko) 2022-09-29 2025-06-12 광조우 조요 파마테크 컴퍼니 리미티드 거대고리 유도체 및 이의 적용
CN118047798A (zh) * 2022-11-16 2024-05-17 杭州阿诺生物医药科技有限公司 一种pan-KRAS抑制剂化合物
CN117534684A (zh) * 2022-11-29 2024-02-09 杭州阿诺生物医药科技有限公司 一种pan-KRAS抑制剂化合物
US20240343813A1 (en) * 2023-02-06 2024-10-17 Bicara Therapeutics Inc. Combination therapy and related methods
IL322109A (en) 2023-02-14 2025-09-01 Hoffmann La Roche Tricyclic compounds for cancer treatment
WO2024187174A2 (en) * 2023-03-09 2024-09-12 Aadigen, Llc Compositions for treating cancer with kras mutations and uses thereof
CR20250458A (es) * 2023-03-30 2025-11-21 Revolution Medicines Inc Composiciones para inducir la hidrólisis de ras gtp y sus usos
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025051241A1 (zh) * 2023-09-06 2025-03-13 劲方医药科技(上海)股份有限公司 大环化合物及其抗体-药物偶联物
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025087431A1 (zh) * 2023-10-27 2025-05-01 贝达药业股份有限公司 泛-kras抑制剂及其在医药上的应用
WO2025093625A1 (en) * 2023-11-01 2025-05-08 F. Hoffmann-La Roche Ag Macrocycle compounds for the treatment of cancer
WO2025119392A1 (zh) * 2023-12-08 2025-06-12 正大天晴药业集团股份有限公司 含有酰胺取代的大环类化合物
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025193628A2 (en) * 2024-03-09 2025-09-18 Aadigen, Llc Compositions for treating cancer with kras mutations and uses thereof
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025252241A1 (zh) * 2024-06-07 2025-12-11 杭州和正医药有限公司 一种大环衍生物及其用途
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101602876B1 (ko) * 2014-07-22 2016-03-11 아주대학교산학협력단 완전한 이뮤노글로불린 형태의 세포질 침투능을 갖는 항체를 이용하여 세포내 활성화된 ras를 억제하는 방법 및 그의 이용
JP7721052B2 (ja) * 2018-12-21 2025-08-12 レヴォリューション・メディスンズ，インコーポレイテッド 協同的結合に関与する化合物及びその使用
US11690915B2 (en) * 2020-09-15 2023-07-04 Revolution Medicines, Inc. Ras inhibitors

Also Published As

Publication number Publication date
US20240108630A1 (en) 2024-04-04
KR20240004436A (ko) 2024-01-11
WO2022212894A1 (en) 2022-10-06
EP4320143A1 (en) 2024-02-14
EP4320143A4 (en) 2025-02-19
BR112023020182A2 (pt) 2023-12-12
AU2022249177A1 (en) 2023-10-19
CA3214155A1 (en) 2022-10-06
TW202308632A (zh) 2023-03-01
CR20230500A (es) 2024-02-13
JP2024512767A (ja) 2024-03-19
IL307396A (en) 2023-12-01

Similar Documents

Publication Publication Date Title
MX2023011608A (es) Metodos para inhibir ras.
CL2021000343A1 (es) Inhibidores peptídicos del receptor de interleucina 23 (divisional de la solicitud n° 201800128)
CO2020002588A2 (es) Composiciones que comprenden un inhibidor de shp2 y metodos para tratar el cáncer
CL2018002505A1 (es) Inhibidores del envejecimiento proteico-proteico wdr5
MX2020000386A (es) Inhibidores heterociclicos de la cinasa atr.
CL2018001358A1 (es) Composiciones que comprenden cepas bacterianas
BR112018074395A2 (pt) derivados de pirazol como inibidores de calicreína plasmática
CO2020007162A2 (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa
ECSP20035222A (es) Derivado de amino-fluoropiperidina como inhibidor de quinasa
BR112018074621A2 (pt) derivados de pirazolopirimidina como inibidores de quinase
MX2023001193A (es) Composicion de un anticuerpo inhibidor de masp-2 para usarse en el tratamiento de un padecimiento asociado con la activacion del complemento dependiente de masp-2.
BR112017017727A8 (pt) Heterociclos bicíclicos como inibidores de fgfr4
MX2018008939A (es) Anticuerpos anti-factor de la coagulacion xi.
CO2020007156A2 (es) Derivado de amino-metil piperidina como inhibidor de quinasa
MX2020009154A (es) Nuc-1031 (gemcitabina-[fenil-benzoxi-l-alaninil])-fosfato) para usarse en el tratamiento neoadyuvante y adyuvante en pacientes con cáncer.
GEAP202215303A (en) Chromane monobactam compounds for the treatment of bacterial infections
MX388890B (es) Metodos para tratar cancer usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton.
BR112022009631A2 (pt) Combinações de inibidores de dgk e antagonistas do ponto de checagem
CL2019002854A1 (es) Compuesto macrocíclico y sus usos.
CL2020003306A1 (es) Composiciones bifuncionales para el tratamiento del cáncer.
BR112018014247A2 (pt) inibição de reação alérgica usando um inibidor il-33
UY38352A (es) Inhibidores de integrina alfavbeta6
MX388815B (es) Inhibidores de il-8 para usarse en el tratamiento de neuropatia periferica inducida por quimioterapia.
MX2021002652A (es) Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares.
BR112015016992A2 (pt) uso de agonistas de receptores alfa 7 nicotínico de acetilcolina para o tratamento, melhoria, prevenção ou demora no progresso da fadiga